{"nct_id":"NCT02626000","title":"Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)","status":"COMPLETED","status_verified_date":"2021-08","start_date":"2016-04-06","start_date_type":"ACTUAL","primary_completion_date":"2017-11-02","primary_completion_date_type":"ACTUAL","completion_date":"2020-08-28","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["AMGN"]}